Document is current

Article History

Received: 5 March 2018

Accepted: 10 September 2018

First Online: 18 September 2018

Ethics approval and consent to participate

: Separate ethical approval is not needed for the current submission. This manuscript presents data analyzing RNA obtained from blood of patients enrolled in two different Pfizer sponsored clinical trials. RNA analysis of the Pfizer study data was contemplated in the original protocol consents and therefore this study does not need ethical approval as the subjects had consented to participate in the two studies and agreed to have their blood drawn and gene expression analyzed. Furthermore the investigators remain totally blinded as to the patient’s identifiers with HIPPA protected data.

: not applicable.

: PF: Advisory Board Member for Seattle Genetics, Regeneron, Aspyrian Therapeutics, Array Biopharma, EMD Serono and Castle Biosciences. Stock equity in MACK, AGN, INCY, ADVM, and CLVS.KW M.D.: no conflicts.KW: President and CEO of CPS Companion Diagnostics. Equity interest in CPS Companion Diagnostics which holds patent related to content of the manuscript.AMC: Chairman of CPS Companion Diagnostics. Equity interest in CPS Companion Diagnostics which holds patent related to content of the manuscript.NB: Consultant for Neon. Advisory Board Member for CPS Companion Diagnostics and Curevac. Equity interest in CPS Companion Diagnostics which holds patent related to content of the manuscript.WKO: Chief Scientific Officer and Chairman of the Science Advisory Board CPS Companion Diagnostics. Equity interest in CPS Companion Diagnostics which holds patent related to content of the manuscript.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.